Vertex Pharmaceuticals (VRTX) Non-Current Deferred Tax Liability (2009 - 2018)

Vertex Pharmaceuticals' Non-Current Deferred Tax Liability history runs 10 years deep, the most recent figure standing at $9.4 million for Q3 2018.

• In Q3 2018, Non-Current Deferred Tax Liability fell 11.87% year-over-year to $9.4 million; the TTM figure through Sep 2018 stood at $9.4 million (down 11.87% YoY), while the FY2017 annual figure was $6.3 million, down 95.27% from the prior year.
• Non-Current Deferred Tax Liability for Q3 2018 stood at $9.4 million, up from $9.3 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $136.6 million in Q2 2017, with the low at $6.3 million in Q4 2017.
• The 5-year median for Non-Current Deferred Tax Liability is $111.2 million (2015), against an average of $74.8 million.
• The sharpest annual moves came in 2016 and 2017: Non-Current Deferred Tax Liability soared 643.78% in 2016, then plunged 95.27% in 2017.
• Vertex Pharmaceuticals' Non-Current Deferred Tax Liability stood at $15.0 million in 2014, then jumped by 631.75% to $110.1 million in 2015, then advanced by 21.78% to $134.1 million in 2016, then plunged by 95.27% to $6.3 million in 2017, then soared by 48.46% to $9.4 million in 2018.
• Business Quant data shows VRTX's Non-Current Deferred Tax Liability at $9.4 million in Q3 2018, $9.3 million in Q2 2018, and $9.6 million in Q1 2018.